Lidocaine Versus Magnesium Sulphate in Management of Myofascial Pain Dysfunction Syndrome

The goal of this clinical trial is to investigate the effectiveness of Magnesium Sulphate in the management of myofascial pain dysfunction syndrome in comparison to Lidocaine and Saline. A total of 75 patients suffering from myofascial pain dysfunction syndrome will be assigned into one of three groups, each with 25 patients. Group A: (Saline) includes patients enrolled for Saline injection into the trigger points. Group B: (Magnesium Sulphate) includes patients enrolled for Magnesium Sulphate injection into the trigger points. Group C: (Lidocaine) includes patients who will be enrolled for Lidocaine injection into the trigger points The primary outcome that will be investigated is (pain with a visual analogue score), and secondary outcomes will be (maximum mouth opening between edges of upper and lower incisors with millimeters, electrical activity with Electromyography, and quality of life assessed using the Oral Health Impact Profile questionnaire) The outcomes will be assessed pre-injection, 1month after injection, 3months after injection, and 6 months after injection

NCT Number	NCT06595017
Lead Sponsor	Misr University for Science and Technology
Conditions	Myofascial Pain Dysfunction Syndrome
Enrollment	75 participants
Start Date	2024-10-01
Primary Completion	2025-09-30 (estimated)
Study Completion	2025-11-30 (estimated)
Updated on ClinicalTrials.gov	2024-09-19